ha-1100 and Demyelinating-Diseases

ha-1100 has been researched along with Demyelinating-Diseases* in 1 studies

Other Studies

1 other study(ies) available for ha-1100 and Demyelinating-Diseases

ArticleYear
Hydroxyfasudil alleviates demyelination through the inhibition of MOG antibody and microglia activation in cuprizone mouse model.
    Clinical immunology (Orlando, Fla.), 2019, Volume: 201

    Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system characterized by oligodendrocyte loss and progressive neurodegeneration. The cuprizone (CPZ)-induced demyelination is widely used to investigate the demyelination/remyelination. Here, we explored the therapeutic effects of Hydroxyfasudil (HF), an active metabolite of Fasudil, in CPZ model. HF improved behavioral abnormality and reduced myelin damage in the corpus callosum. Splenic atrophy and myelin oligodendrocyte glycoprotein (MOG) antibody were observed in CPZ model, which were partially restored and obviously inhibited by HF, therefore reducing pathogenic binding of MOG antibody to oligodendrocytes. HF inhibited the percentages of CD4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Behavior, Animal; Brain; CD4-Positive T-Lymphocytes; Cuprizone; Cytokines; Demyelinating Diseases; Disease Models, Animal; Macrophages; Male; Mice, Inbred C57BL; Motor Activity; Spleen

2019